Internal Medicine, Endocrinology, Diabetes, & Metabolism · Pomona, CA
NPI
1336117738
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
1904 N Orange Grove Ave, Chaparral Medical Group
Pomona, CA, 91767
Phone (909) 469-1823
Groups this clinician bills Medicare through
Medicare paid, 2024
$67K
792 services
Medicare patients, 2024
201
Average age 72
Drug cost, 2024
$2.8M
7,858 prescriptions
Company payments, 2025
$512
From 12 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Rita K Pradhan was code 99215 (office e&m - established), 264 times for 112 patients. In total Rita K Pradhan billed 792 services in 21 codes, and Medicare paid $67K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-02-20.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Office | 264 | 112 | $137.83 | $36K |
| 99214 Office E&M - Established | Office | 160 | 90 | $89.88 | $14K |
| 99205 Office E&M - New | Office | 28 | 28 | $174.53 | $4,887 |
| 96372 Injection Administration | Office | 26 | 17 | $12.14 | $316 |
| 95251 Test - Miscellaneous | Office | 25 | 14 | $25.43 | $636 |
By year: 2022 $61K for 2,211 services; 2023 $77K for 1,486 services; 2024 $67K for 792 services.
Medicare prescription drug claims, 2024
In 2024, the drug Rita K Pradhan prescribed most often to Medicare patients was Levothyroxine Sodium, with 1,033 prescriptions and refills. In total Rita K Pradhan wrote 7,858 Medicare prescriptions that cost $2.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 1,033 | 2,494 | 235 | $11K |
| Atorvastatin Calcium Generic | 541 | 1,482 | 169 | $5,620 |
| Jardiance Empagliflozin | 493 | 818 | 104 | $458K |
| Metformin Hcl Generic | 448 | 1,218 | 144 | $3,987 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 341 | 815 | 99 | $46K |
| Ozempic Semaglutide | 314 | 496 | 67 | $448K |
| Farxiga Dapagliflozin Propanediol | 232 | 382 | 53 | $203K |
| Tradjenta Linagliptin | 220 | 334 | 39 | $165K |
| Ezetimibe Generic | 175 | 449 | 50 | $3,996 |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 173 | 444 | 70 | $17K |
| Losartan Potassium Generic | 169 | 435 | 46 | $1,495 |
| Prolia Denosumab | 155 | 805 | 92 | $262K |
| Humalog Kwikpen U-100 Insulin Lispro | 142 | 369 | 52 | $27K |
| Rosuvastatin Calcium Generic | 141 | 387 | 40 | $2,597 |
| Glimepiride Generic | 133 | 325 | 35 | $1,005 |
Brand drugs: 3,391 claims; generic drugs: 4,065 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Rita K Pradhan $512 ($512 in general payments such as food, travel and fees) from 12 companies. The largest payer was Amgen Inc. with $119.
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. AMGN | 5 | $119 |
| Insulet Corporation PODD | 2 | $60.08 |
| Novo Nordisk Inc NVO | 2 | $50.8 |
| Lilly USA, LLC LLY | 2 | $49.69 |
| GlaxoSmithKline, LLC. GSK | 3 | $48.65 |
| Abbott Laboratories ABT | 2 | $45.07 |
| Ascendis Pharma Endocrinology Inc ASND | 1 | $28.32 |
| Recordati_rare_diseases_inc. | 1 | $23.65 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 1 | $22.48 |
| Madrigal Pharmaceuticals MDGL | 1 | $22.42 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.